Montelukast prescribing across the NHS.
Montelukast moves 4.9m items a year for £4.6m, 93p an item, add-on asthma therapy at commodity prices. Volume is flat; the interesting recent history is regulatory, with the 2019 warnings about mood and behavioural effects, especially in children, adding caution to a very routine drug.
The NHS in England dispensed 4,901,157 prescription items of Montelukast in the 12 months to July 2026, across primary care and hospitals.
Spending on Montelukast over those 12 months was £4.3m at net ingredient cost, the list price of what was dispensed before any discounts.
Items were up 0.0% on the previous 12 months.
98% of Montelukast volume moved through primary care and 2% through hospital pharmacies.
Montelukast is the largest of 2 chemical substances in Leukotriene receptor antagonists (BNF 3.3.2), by items dispensed.
Among Integrated Care Boards, NHS North East and North Cumbria ICB dispensed the highest volume of Montelukast.
Source: NHS Business Services Authority open data (English Prescribing Data and SCMD), OGL v3.0. Items count prescriptions dispensed, not patients treated.
Diamond markers show events around this period: NICE decisions, safety alerts, supply notices, Drug Tariff moves and price concessions, new suppliers in dm+d and framework awards. Hover a marker for the date and type. The evidence behind each one, with the source quote and link, sits behind Apply.
| Month | Items | Spend (NIC) |
|---|---|---|
| July 2026 | 430,984 | £379k |
| June 2026 | 416,243 | £339k |
| May 2026 | 397,072 | £326k |
| April 2026 | 406,836 | £333k |
| March 2026 | 415,905 | £326k |
| February 2026 | 378,320 | £295k |
| January 2026 | 413,598 | £323k |
| December 2025 | 431,359 | £396k |
| November 2025 | 389,168 | £355k |
| October 2025 | 422,046 | £396k |
| September 2025 | 412,391 | £407k |
| August 2025 | 387,235 | £378k |
The same series as the chart, most recent month first. The full monthly history, as CSV, sits behind Apply.
100.0% of its class.
Montelukast is the largest of 2 chemical substances in Leukotriene receptor antagonists (BNF 3.3.2), by items dispensed in July 2026. The full class league, who's gaining, and the month-by-month share movement sit behind Apply.
Average items by calendar month across the full history, indexed to the annual mean.
23 suppliers hold a live montelukast listing, across 57 packs.
A A H Pharmaceuticals Ltd, Accord-UK Ltd, Alliance Healthcare (Distribution) Ltd, Almus Pharmaceuticals Ltd, Amarox Ltd, Bristol Laboratories Ltd, Crescent Pharma Ltd, CST Pharma Ltd, Dr Reddy's Laboratories (UK) Ltd, Glenmark Pharmaceuticals Europe Ltd, Krka UK Ltd, Medihealth (Northern) Ltd, Milpharm Ltd, Organon Pharma (UK) Ltd, Relonchem Ltd, Rivopharm (UK) Ltd, Sandoz Ltd, Sigma Pharmaceuticals Plc, Sun Pharma UK Ltd, Teva UK Ltd, Tillomed Laboratories Ltd, Torrent Pharma (UK) Ltd, TriOn Pharma Ltd. In the last twelve months 0 packs were listed and 2 discontinued. Every pack, its GTIN and published list price, and each week's changes are in the full report.
A listing in the NHS Dictionary of Medicines and Devices means a product may be supplied. It says nothing about sales or market share, and the list price is the reimbursement price, not what any buyer pays. Contains information from dm+d 10.1.0, published by the NHS Business Services Authority under the Open Government Licence v3.0.
Montelukast across all 36 ICBs.
Every Integrated Care Board in England, shaded by how much montelukast its GPs dispense per head of population. Hover an ICB to name it. The ranked figures for all 36 ICBs, and the drill-down to practice level, are in the full report.
Darker shading marks where Montelukast is dispensed most per head of population. Exact figures for every ICB, and the drill-down to practice level, are in the full report.
Zoomed out to the 7 NHS regions.
The same 12 months rolled up to NHS England's seven regions, ranked by intensity.
The teaser view.
Three rows each. The full 36-ICB view, every prescribing organisation, every strength and the hospital picture sit below the fold, behind Apply.
- 1 NHS North East and North Cumbria ICB 408k
- 2 NHS Greater Manchester ICB 294k
- 3 NHS West Yorkshire ICB 263k
- – + 33 more. See the full 36-ICB table. See all →
- 1 NHS North East and North Cumbria ICB +2.5%
- 2 NHS South Yorkshire ICB +2.2%
- 3 NHS Essex ICB +2.2%
- – + 33 more. See every ICB, ranked. See all →
- 1 Montelukast 10mg tablets 90%
- 2 Montelukast 5mg chewable tablets sugar free 7%
- 3 Montelukast 4mg chewable tablets sugar free 2%
- – + 3 more. See every strength and pack. See all →
Split of items across NHSBSA primary care and SCMD hospital dispensing.
Prescribing by deprivation.
Items per 1,000 registered patients by deprivation decile (1 = most deprived), practice deprivation weighted by where each practice's patients live. Read the shape rather than the absolute level: the most and least deprived deciles cover far fewer practices, and age structure drives much of the gradient.
The devolved nations.
| Nation | Items · 12 months | Data to |
|---|---|---|
| England | 4.9m | July 2026 |
| Scotland | 338k | June 2026 |
| Northern Ireland | 158k | May 2026 |
| Wales | 344k | April 2026 |
Each nation publishes its own community prescribing data, with different coding and list rules, so read these per-nation rather than as an exact UK total. Sources: NHSBSA (England), Public Health Scotland, NHS Wales Shared Services Partnership, OpenDataNI. Used under the Open Government Licence v3.0.
What open data won't tell you about montelukast.
Whether those warnings changed prescribing is hard to read in a flat national line; whatever effect exists is smaller than the noise.
Asked and answered.
Is montelukast prescribing rising or falling in the NHS?
Rising. England dispensed 4,901,157 items of Montelukast in the 12 months to July 2026, up 0.0% on the previous 12 months. Items count prescriptions dispensed, not patients treated, so the change can reflect dose and duration shifts as well as patient numbers.
How much does the NHS spend on montelukast?
£4.3m at net ingredient cost in the 12 months to July 2026. Net ingredient cost is the list price of the medicine before discounts and rebates; the NHS's final bill, especially for hospital medicines, is usually lower.
Where in England is montelukast prescribed most?
By raw volume, NHS North East and North Cumbria ICB dispensed the most montelukast in the last 12 months. Raw volume favours the biggest populations; the map on this page shades every ICB by items per head to correct for that.
How up to date is this data?
This page runs to July 2026, the most recent NHSBSA release. Prescribing data publishes roughly six to eight weeks in arrears, and DoseTrend refreshes within 48 hours of each monthly release.
The full breakdown.
Every ICB, every prescribing organisation, every strength, the hospital view with what trusts paid and who holds each framework line, Signals with their sources, and the monthly briefing PDF. The rows below are placeholders; the real tables sit behind the application.
Track montelukast like this, every month.
£1,500 a month per molecule. Apply and we'll pre-fill Montelukast for you.